Dublin, June 11, 2021 (GLOBE NEWSWIRE) -- The "Next-Generation Sequencing: Emerging Clinical Applications and Global Markets 2020-2025" report has been added to ResearchAndMarkets.com's offering.
The global market for clinical next-generation sequencing (NGS) should grow from $5.9 billion in 2020 to $22.9 billion by 2025 with a compound annual growth rate (CAGR) of 31.4% for the period of 2020-2025.
The scope of the report includes clinical NGS technologies, applications, industries, initiatives, patents and companies. The markets for NGS-based diagnostics are given for the years 2019, 2020 and 2025.
This report reviews the main sequencing technologies and explains why genetic variation is important in clinical testing. It then discusses some of the significant research initiatives that impact clinical NGS applications. Liquid biopsy formats are discussed. The main market driving forces are also discussed.
The report examines the markets by test complexity, clinical indication and test purpose. Test complexity refers to the plex level (i.e., the number of genetic markers that can be analyzed within a sample) and coverage (e.g., the extent to which the genome is covered) of the test. Examining the market by test complexity provides valuable insight into which products (e.g., sample preparation, NGS instrument, informatics, etc.) will be in demand in the future.
The report provides market data and forecasts for NGS diagnostics by specific applications, including those for oncology, cardiovascular diseases, clinical microbiology/infectious diseases, Mendelian disorders, metabolic/immune disorders, neurological disorders, reproductive health and transplant medicine.
Specific geographic markets are discussed, including North America, Europe, Asia-Pacific and the rest of the world.
Industry sectors analyzed include DNA sequencing instruments; long-read sequencing; sequencing informatics; target enrichment; CTC capture and detection; liquid biopsy; cancer screening/early detection; direct to consumer testing; and noninvasive prenatal testing.
The Report Includes
29 data tables and 73 additional tables
An updated review of the global market for emerging clinical applications of the next-generation sequencing (NGS) based diagnostics and related technologies
Analyses of the global market trends, with data from 2019-2020, and projections of compound annual growth rates (CAGRs) through 2025
Discussion of market opportunities for clinical NGS products, clinical applications, industry structure, regulatory scenario, and penetration of NGS-based diagnostics and technologies within the industry
Estimation of the current market size and revenue forecasts for the global NGS diagnostic markets, and corresponding market share analysis by disease indication, test complexity, test purpose, application and geographic region
Evaluation of the key NGS workflow portions of the industry (e.g., sequencing instruments, pre-sequencing target preparation and capture, and post-sequencing data analysis) and the main clinical indications where NGS will capture significant market share by 2025
Assessment of main sequencing technologies and explanation of the importance of genetic variation in clinical testing as well as some of the significant research initiatives affecting clinical NGS applications
A summary of the major acquisitions and strategic alliances in the clinical NGS industry from January 2019 through April 2021, including key alliance trends
Patent review and significant allotments of the U.S. patents in the liquid biopsy industry
Company profiles of the major market players, including Agilent Technologies Inc., Becton, Dickinson and Co. (BD), Koninklijke Philips N.V., Merck KGaA, Novogene Co. Ltd., Oxford Nanopore Technologies Ltd., Qiagen NV, Roche Holding AG, and Thermo Fisher Scientific Inc.
Key Topics Covered:
Chapter 1 Introduction
Chapter 2 Summary and Highlights
Chapter 3 Overview
Liquid and Tissue Biopsy
Clinical NGS Testing Market
Growth Drivers of Clinical NGS
Chapter 4 Technology Background
Importance of DNA
Genetic Variation and Analysis
Genetic Analysis Technologies
Sequencing in Clinical Applications
History of DNA Sequencing
Sanger Sequencing Technology
Mapping to a Reference Sequence
Artificial Intelligence Technologies
Clinical Sequencing Technology Challenges
Chapter 5 Clinical NGS Initiatives
R&D Initiatives and Programs
1+ Million Genomes
Access to Treatment and Testing (ACTT)
Access to Comprehensive Genomic Profiling Coalition (ACGP)
Africa Pathogen Genomics Initiative
Blood Profiling Atlas
Cancer Moon Shots Program
China Precision Medicine Initiative
CTC Trap Consortium
Early Cancer Detection Consortium
France Genomic Medicine Plan
Friends of Cancer Research Project
Genomic Medicine Sweden
Human Cell Atlas
Human Immunomics Initiative
Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy Program
Liquid Biopsies and Imaging for Improved Cancer Care
Liquid Biopsy-Based Malignant Tumor Early Screening Technology Research and Development Project
Liver Cancer Early Screening Comprehensive Prevention and Control Project
Lung Cancer Genomic Screening Project for Individualized Medicine in Asia
Million Veteran Program
Medical Genome Initiative
Precision Medicine Initiative
Target ALS Diagnosis Initiative
Treehouse Childhood Cancer Initiative
Very Rare Cancer Consortium
Worldwide Innovative Networking (WIN) Consortium
Cambridge Single-Cell Analysis Core Facility
Harvard Medical School Single-Cell Core
Mayo Medical Genome Facility
National Center for Single-Cell Biology
Next-Generation Single-Cell Analysis Program
Single-Cell Analysis Core
UC San Francisco Single-Cell Analysis Center
Population Sequencing Projects
Chapter 6 Clinical NGS Applications
Liquid Biopsy Biomarkers
Mendelian Disorders Applications
Reproductive Health Applications
Noninvasive Prenatal Testing
Microbiology and Infectious Disease Applications
Complex Disorders Applications
Chapter 7 Clinical NGS Industry
Sequencing Instrument Industry
Third-Generation Sequencing Industry
Sequencing Informatics Industry
Target Enrichment and Amplification Industry
CTC Capture and Detection Industry
Liquid Biopsy Assay Industry
Liquid Biopsy Cancer Screening/Early Detection Industry
Health-Focused DTC Genetic Testing Industry: Two Market Models
DTC Clinical Health Genetic Testing Industry
Noninvasive Prenatal Testing (NIPT) Industry
Chapter 8 Acquisitions and Strategic Alliances
Chapter 9 Clinical NGS Markets
Impact of COVID-19 on the Clinical NGS Markets
Clinical NGS Market by Disease Category
NGS Mendelian Disorders
Microbiology and Infectious Diseases
Global Market for NGS in Oncology by Region
Global Market for NGS in Reproductive Health by Region
Chapter 10 Patent Review
Patents on Circulating Tumor Cells
Patents on Exosomes
Patents on Cell-Free DNA
Patents Related to Biomarkers
Patent Considerations for the Use of Artificial Intelligence in Cancer Diagnostics
Liquid Biopsy Patent Litigation
Chapter 11 Company Profiles
Adaptive Biotechnologies Inc.
Agilent Technologies Inc.
Amoy Diagnostics Co. Ltd.
Arcedi Biotech Aps
Armonica Technologies Inc.
Aviva Biomed Inc.
Bard1 Life Sciences Ltd.
Becton, Dickinson And Co.
Berry Genomics Co. Ltd.
Biological Dynamics Inc.
Bluestar Genomics Inc.
Burning Rock Biotech Ltd.
Cancer Genetics Inc.
Captis Diagnostics Inc.
Caris Life Science
Cell Microsystems Inc.
Centrillion Genomics Technologies
Clinical Genomics Technologies
Cygnus Biosciences Co. Ltd.
Datar Cancer Genetics Ltd.
Dovetail Genomics Llc
Eone-Diagnomics Genome Center
Epic Sciences Inc.
Exact Sciences Corp.
Exosome Sciences Inc.
Ezlife Bio Inc.
Fluxion Biosciences Inc.
Fulgent Genetics Inc.
Full Genomes Corp. Inc.
Gene By Gene Ltd.
Genetron Health Technologies
Geneseq Biosciences Pty Ltd.
Genexosome Technologies Inc.
Guardant Health Inc.
Helix Opco Llc
Htg Molecular Diagnostics Inc.
Inex Innovate Pte. Ltd.
Interpace Biosciences Inc.
Jabrehoo Medtech Co., Ltd.
Jbs Science Inc.
Jumpcode Genomics Inc.
Koninklijke Philips N.V.
Laboratory Corp. Of America Inc.
Labgenomics Co., Ltd.
Labrinth Biotech Inc.
Lariat Biosciences Inc.
Liquid Biopsy Labs
Lucence Diagnostics Pte. Ltd.
Lunglife Ai Inc.
Menarini Silicon Biosystems Spa
Micareo Rare Cell Diagnostics
Myriad Genetics Inc.
Nanostring Technologies Inc.
Nanoview Biosciences Inc.
Neo New Oncology Gmbh
New England Biolabs
New Horizon Health Ltd.
Novogene Co. Ltd.
Nx Prenatal Inc.
Oncimmune Holdings Plc
Orchid Health Inc.
Oxford Nanopore Technologies Ltd.
Pacific Biosciences Of California Inc.
Personal Genome Diagnostics Inc.
Quantum Biosystems Inc.
Quest Diagnostics Inc.
Real Time Genomics Inc.
Resolution Bioscience Inc.
Roche Holding Ag
Saga Diagnostics Ab
Seracare Life Sciences Inc.
Seven Bridges Genomics Inc.
Singlera Genomics Inc.
Stage Zero Life Sciences
Strand Life Sciences Pvt. Ltd.
Stratos Genomics Inc.
Sysmex Inostics Gmbh
Tailai Biosciences Co., Ltd.
Takara Bio Inc.
Thermo Fisher Scientific Inc.
Ubiquity Genomics Inc.
Universal Diagnostics Sl
Xing Technologies Llc
Yourgene Health Plc
Yikon Genomics Co. Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/uh658b
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900